Peterson Wealth Services Has $1.90 Million Position in Zoetis Inc. $ZTS

Peterson Wealth Services raised its stake in Zoetis Inc. (NYSE:ZTS) by 43,297.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,057 shares of the company’s stock after buying an additional 16,020 shares during the period. Peterson Wealth Services’ holdings in Zoetis were worth $1,898,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Global Wealth Strategies & Associates bought a new position in shares of Zoetis during the fourth quarter worth about $25,000. Prosperity Bancshares Inc bought a new stake in Zoetis in the fourth quarter valued at approximately $25,000. Lodestone Wealth Management LLC acquired a new stake in Zoetis during the 4th quarter valued at approximately $30,000. Root Financial Partners LLC increased its position in Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. Finally, KERR FINANCIAL PLANNING Corp acquired a new stake in Zoetis during the 3rd quarter valued at approximately $31,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Zoetis stock opened at $75.06 on Friday. The stock has a market capitalization of $31.47 billion, a price-to-earnings ratio of 12.45, a PEG ratio of 1.17 and a beta of 0.75. Zoetis Inc. has a 52-week low of $71.47 and a 52-week high of $161.77. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The stock’s 50 day moving average price is $80.73 and its two-hundred day moving average price is $107.98.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the prior year, the firm earned $1.48 EPS. The business’s revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is 35.16%.

Insider Buying and Selling at Zoetis

In other news, Director Frank A. Damelio bought 6,650 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the purchase, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul Bisaro bought 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the transaction, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 11,650 shares of company stock valued at $886,384. Corporate insiders own 0.22% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of recent analyst reports. Argus restated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Barclays decreased their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, HSBC decreased their price target on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a report on Monday. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $123.46.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.